Gables Capital Management’s Novo Nordisk NVO Stock Holding History

Gables Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.4K	Sell	675 -1,100	-62%	-$47.3K	0.01%	295
2026 Q1	$65.2K	Hold	1,775	–	–	0.03%	207
2025 Q4	$90.3K	Sell	1,775 -125	-7%	-$6.39K	0.04%	187
2025 Q3	$105K	Hold	1,900	–	–	0.05%	165
2025 Q2	$131K	Hold	1,900	–	–	0.06%	144
2025 Q1	$132K	Hold	1,900	–	–	0.07%	150
2024 Q4	$163K	Buy	1,900 +1,000	+111%	+$108K	0.08%	140
2024 Q3	$107K	Buy	+900	New	+$120K	0.05%	158
2023 Q2	–	Sell	-800	Closed	-$63.7K	–	380
2023 Q1	$63.7K	Sell	800 -400	-33%	-$28.4K	0.04%	169
2022 Q4	$81.2K	Buy	+1,200	New	+$70.4K	0.06%	160

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Gables Capital Management's NVO Position: Q2 2026 in Review

Gables Capital Management reduced its Novo Nordisk (NVO) stake by 62% in Q2 2026, selling an estimated $47.3K and leaving 675 shares worth $32.4K. The position accounts for 0.01% of the portfolio, ranked #295.

Gables Capital Management first reported a position in NVO in Q4 2022 and has held it in 10 quarters since. The position peaked at $163K in Q4 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Gables Capital Management held 675 shares of Novo Nordisk worth $32.4K as of Q2 2026.
Gables Capital Management sold 1,100 Novo Nordisk shares in Q2 2026, an estimated $47.3K.
Novo Nordisk made up 0.01% of Gables Capital Management's portfolio in Q2 2026, its #295 holding.
Gables Capital Management first reported a position in Novo Nordisk in Q4 2022 and has held it in 10 quarters since.
Gables Capital Management's Novo Nordisk position peaked at $163K in Q4 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Gables Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.